Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 6/20 | 0.43 |
| ▸ | DRD4 | P21917 | 6/20 | 0.43 |
| ▸ | HRH2 | P25021 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 6/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.43 |
| ▸ | HRH1 | P35367 | 6/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | DRD3 | P35462 | 6/20 | 0.43 |
| ▸ | HTR6 | P50406 | 6/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 6/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 6/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 6/20 | 0.43 |
| ▸ | DRD5 | P21918 | 5/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.43 |
| ▸ | HTR7 | P34969 | 5/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.43 |
| ▸ | HTR1A | P08908 | 5/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8236341 | 1.00 | SLC6A3 (0.43) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL13780831 | 0.93 | AGTR2 (0.40) | HTR2CRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14299751 | 0.85 | SLC6A3 (0.42) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL4289800 | 0.75 | CYP3A4 (0.43) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL4281572 | 0.71 | MEN1 (0.42) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL8233262 | 0.71 | MEN1 (0.42) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL7264075 | 0.66 | ACE (0.53) | HTR2CRAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4291616 | 0.66 | CYP3A4 (0.43) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL13780832 | 0.66 | CYP3A4 (0.43) | SLC6A3CACNA1FDRD4HRH2HTR2A | |
| SCHEMBL7264101 | 0.66 | ACE (0.53) | HTR2CRAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | claimed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | claimed |
| EP-1987009-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2008-11-05 | — | — | EP | claimed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | claimed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-02-04 | — | — | US | disclosed |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-08-04 | — | — | US | disclosed |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION | 2019-07-18 | — | — | US | disclosed |
| US-8354434-B2 | Cyclourea compounds as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2012-12-20 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | disclosed |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | PURDUE PHARMA L.P. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1987009-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007085357-A1 | CYCLOUREA COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322830-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | SLC6A3 640/4885CACNA1F 10/4885DRD4 1009/4885 |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SLC6A3 1036/4885CACNA1F 6/4885DRD4 2680/4885 |
| US-10729664-B2 | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents | TRPV1, CACNA1B, ORAI1 | SLC6A3 1036/4885CACNA1F 6/4885DRD4 2680/4885 |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SLC6A3 1036/4885CACNA1F 6/4885DRD4 2680/4885 |
| US-20090176838-A1 | Cyclourea Compounds as Calcium Channel Blockers | CACNA1E, CACNA1B, CACNA1D | SLC6A3 640/4885CACNA1F 10/4885DRD4 1009/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | SLC6A3 586/4885CACNA1F 82/4885DRD4 2125/4885 |
| US-20190216747-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SLC6A3 1036/4885CACNA1F 6/4885DRD4 2680/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | SLC6A3 1036/4885CACNA1F 6/4885DRD4 2680/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | SLC6A3 1023/4885CACNA1F 6/4885DRD4 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.